FORM 8-K

                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                      the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): January 31, 2005

                           DUSA PHARMACEUTICALS, INC.
             (Exact name of registrant as specified in its charter)


  NEW JERSEY                        0-19777                        22-3103129
(State or other                   (Commission                    (IRS Employer
jurisdiction of                   File Number)                   Identification
 incorporation)                                                     Number)

                           DUSA PHARMACEUTICALS, INC.
                                 25 UPTON DRIVE
                        WILMINGTON, MASSACHUSETTS 01887
          (Address of principal executive offices, including ZIP code)

                                 (978) 657-7500
              (Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]      Written communications pursuant to Rule 425 under the Securities Act
         (17 CFR 230.425)

[ ]      Soliciting material pursuant to Rule 14a-12 under the Securities Act
         (17 CFR 240.14a-12)

[ ]      Pre-commencement communications pursuant to Rule 14d-2(b) under the
         Exchange Act (17 CFR 240.14a-12(b))

[ ]      Pre-commencement communications pursuant to Rule 13e-4(c) under the
         Exchange Act (17 CFR 240.13e-4(c))



ITEM 8.01.        OTHER EVENTS.

DUSA Pharmaceuticals, Inc. ("DUSA") issued a press release today attached to
and made a part of this report which announced that it had filed a lawsuit
against The Cosmetic Pharmacy of Tucson, Arizona alleging violations of the
Lanham Act for false advertising and trademark infringement and of U.S. patent
law. The suit has been filed in the United States District Court for the
District of Arizona.

In addition, DUSA believes that certain actions of The Cosmetic Pharmacy go
beyond the activities which are permitted under the Food, Drug and Cosmetic
Act, and, as a result, it has advised the U.S. Food and Drug Administration
(FDA) and Arizona State Board of Pharmacy of its concerns.

Except for historical information, this current report contains certain
forward-looking statements that involve known and unknown risks and
uncertainties, which may cause actual results to differ materially from any
future results, performance or achievements expressed or implied by the
statements made. These forward-looking statements relate to the Company's
belief regarding The Cosmetic Pharmacy activities and its intention to protect
its product's reputation and other risks identified in DUSA's SEC filings from
time to time.

ITEM 9.01.        FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits

[99]     Press Release dated January 31, 2005.



                                   SIGNATURES


         Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.

                                        DUSA PHARMACEUTICALS, INC.

Dated: January 31, 2005                 By: /s/ D. Geoffrey Shulman
                                            -----------------------------------
                                            D. Geoffrey Shulman, MD, FRCPC 
                                            Chairman of the Board and
                                            Chief Executive Officer



                                 EXHIBIT INDEX




NO.             DESCRIPTION

             
99              Press Release dated January 31, 2005